Pacira BioSciences, Inc. (PCRX)

Financial leverage ratio

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Total assets US$ in thousands 1,553,520 1,521,690 1,646,820 1,583,320 1,574,390 1,534,460 1,542,380 1,523,420 1,681,200 1,734,360 1,733,990 1,891,480 2,075,350 1,356,000 1,325,830 1,287,550 1,274,510 1,220,270 866,111 821,379
Total stockholders’ equity US$ in thousands 778,348 749,583 879,278 892,162 870,130 831,551 807,975 768,041 775,010 770,123 756,636 709,576 730,408 718,602 687,168 650,818 619,688 584,690 388,148 374,037
Financial leverage ratio 2.00 2.03 1.87 1.77 1.81 1.85 1.91 1.98 2.17 2.25 2.29 2.67 2.84 1.89 1.93 1.98 2.06 2.09 2.23 2.20

December 31, 2024 calculation

Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $1,553,520K ÷ $778,348K
= 2.00

The financial leverage ratio of Pacira BioSciences, Inc. has shown fluctuations over the period from March 31, 2020, to December 31, 2024. The ratio measures the company's reliance on debt financing compared to equity.

The ratio started at 2.20 on March 31, 2020, indicating higher debt levels relative to equity. Over the next few quarters, the ratio increased slightly before showing a declining trend. By March 31, 2021, the ratio had decreased to 1.98, indicating a reduction in debt relative to equity.

From March 31, 2021, to June 30, 2022, the financial leverage ratio continued to decrease steadily, reaching a low of 1.77 by March 31, 2024. This decline suggests the company was reducing its debt levels compared to equity, which can be a positive sign for investors concerned about financial risk.

However, the ratio saw a slight increase in the subsequent quarters, reaching 2.00 by December 31, 2024. This uptick indicates a slight increase in debt levels compared to equity, which could be a signal that the company is taking on more debt for potential growth or investment opportunities.

Overall, the financial leverage ratio of Pacira BioSciences, Inc. has shown variability over the analyzed period, with fluctuations in the company's debt-to-equity structure impacting its financial leverage position. Investors and analysts may want to closely monitor this ratio to assess the company's financial risk and capital structure strategy.